Menlo Therapeutics is a clinical stage biopharmaceutical company focused on the treatment of chronic itch and chronic refractory cough. Serlopitant, a potent and highly specific NK1 receptor antagonist, is an investigational drug that acts through a novel mechanism to interrupt itch and potentially cough. Serlopitant may be a first in class once-daily oral tablet therapy for relief of itch or cough.
Menlo Therapeutics
